Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimmo Porkka

Showing results (11-20 of 142) with videos related to

Pageof 15
Sort By:
Duodecim; Laaketieteellinen Aikakauskirja|April 18, 2012
[Current therapy of chronic myeloid leukemia]Hanna Koskela, Perttu Koskenvesa, Satu Mustjoki, et al.
Leukemia Research|April 10, 2022
Incidence of myelodysplastic syndromes in Finland 1997-2016Suvi Kontro, Jani Raitanen, Kimmo Porkka, et al.
Nature Medicine|June 8, 2002
A tumor-homing peptide with a targeting specificity related to lymphatic vesselsPirjo Laakkonen, Kimmo Porkka, Jason A Hoffman, et al.
Patient Preference and Adherence|December 5, 2014
Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physiciansMeri Kekäle, Kimmo Talvensaari, Perttu Koskenvesa, et al.
Current Drug Targets|December 15, 2010
Interferon alpha for treatment of chronic myeloid leukemiaBengt Simonsson, Henrik Hjorth-Hansen, Ole Weis Bjerrum, et al.
Oncoimmunology|August 2, 2014
Dasatinib promotes Th1-type responses in granzyme B expressing T-cellsAnna Kreutzman, Mette Ilander, Kimmo Porkka, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 29, 2002
A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivoKimmo Porkka, Pirjo Laakkonen, Jason A Hoffman, et al.
Annals of Hematology|February 6, 2026
Novel therapies in myeloid neoplasms show limited benefit and increased costs over 15 years of follow-up in Southern FinlandTheerin Lanamtieng, Anna Mervaala-Muroke, Laura Toivanen, et al.
Leukemia & Lymphoma|June 20, 2013
Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapyMette Ilander, Perttu Koskenvesa, Sari Hernesniemi, et al.
Leukemia & Lymphoma|May 24, 2012
Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemiaJuan Luis Steegmann, Francisco Cervantes, Philipp le Coutre, et al.
Pageof 15

Showing results (11-20 of 142) with videos related to

Sort By:
Pageof 15
Duodecim; Laaketieteellinen Aikakauskirja|April 18, 2012
[Current therapy of chronic myeloid leukemia]Hanna Koskela, Perttu Koskenvesa, Satu Mustjoki, et al.
Leukemia Research|April 10, 2022
Incidence of myelodysplastic syndromes in Finland 1997-2016Suvi Kontro, Jani Raitanen, Kimmo Porkka, et al.
Nature Medicine|June 8, 2002
A tumor-homing peptide with a targeting specificity related to lymphatic vesselsPirjo Laakkonen, Kimmo Porkka, Jason A Hoffman, et al.
Patient Preference and Adherence|December 5, 2014
Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physiciansMeri Kekäle, Kimmo Talvensaari, Perttu Koskenvesa, et al.
Current Drug Targets|December 15, 2010
Interferon alpha for treatment of chronic myeloid leukemiaBengt Simonsson, Henrik Hjorth-Hansen, Ole Weis Bjerrum, et al.
Oncoimmunology|August 2, 2014
Dasatinib promotes Th1-type responses in granzyme B expressing T-cellsAnna Kreutzman, Mette Ilander, Kimmo Porkka, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 29, 2002
A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivoKimmo Porkka, Pirjo Laakkonen, Jason A Hoffman, et al.
Annals of Hematology|February 6, 2026
Novel therapies in myeloid neoplasms show limited benefit and increased costs over 15 years of follow-up in Southern FinlandTheerin Lanamtieng, Anna Mervaala-Muroke, Laura Toivanen, et al.
Leukemia & Lymphoma|June 20, 2013
Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapyMette Ilander, Perttu Koskenvesa, Sari Hernesniemi, et al.
Leukemia & Lymphoma|May 24, 2012
Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemiaJuan Luis Steegmann, Francisco Cervantes, Philipp le Coutre, et al.
Pageof 15